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Improvements in clinical management of lung cancer
have been modest over the last 20 years and with
almost 1.6 million deaths worldwide (19% of the
total) it still has the highest mortality rate among
cancers. So far no valid biomarker has proven to be
useful in lung cancer clinical practice and in
reducing mortality. Technical limitations, as well as
genetic and biological tumor heterogeneity have
likely limited the successful identiﬁcation of tumor-
speciﬁc markers. An interesting landmark to identify
novel and more reliable biomarkers is searching for
candidates by looking not only at the tumor itself
but also at the interplay between the tumor and the
host with the aim to identify changes related to the
biological reactivity of the host to a developing
cancer.
MicroRNAs (miRNAs) are 19 to 25 nucleotide-long
non-coding RNAs regulating gene expression by binding
complementary sequences of target mRNAs. MicroRNAs
have a role in cell-to cell communication and are
actively released in the extracellular space included in
vesicles or bounded to proteins protecting them from
RNase activity. In this respect, circulating microRNAs
represent ideal candidates since biomarkers could
reﬂect both the early changes in the pulmonary envi-
ronment or the cross-talk between the tumor and its
surrounding microenvironment.
MicroRNAs-based liquid biopsies are emerging as
promising tools for individual risk stratiﬁcation, for the
diagnosis and prognosis of lung cancer and more
recently as predictive biomarkers of response to therapy.
In our Institution, a speciﬁc circulating microRNA sig-
natures classiﬁer (MSC) was generated and validated in
plasma samples collected from volunteers enrolled in
Low Dose Computed Tomography (LDCT) lung cancer
screening trials, in order to set-up a minimally invasive
test able to detect lung cancer in its early stages. LDCT
is considered the gold standard for the early detection
of lung cancer. Results of a USA randomized screening
trial reported a signiﬁcant increase in the number of
lung cancer diagnoses, especially at lower stages, and aJournal of Thoracic Oncology Vol. 11 No. 2S: S2-S15reduction of mortality up to 20%. On the other hand, two
major issues emerged from screening studies: the high
number of false positive cases identiﬁed by LDCT (over
95%) and the overdiagnosis issue (estimated over 18%
in the NLST trial), leading to further examinations or
unnecessary surgical procedures with remarkable
increasing of costs and morbidities.
The MSC stratiﬁes patients in 3 levels of risk: high,
intermediate and low. In large retrospective studies
using plasma samples collected from more than 1000
volunteers enrolled in the INT/IEO and in the MILD
screening trials, the MSC resulted in 87% sensitivity,
81% speciﬁcity and 99% negative predictive value.
Moreover, the combined use of LDCT and the MSC test
showed a 5-fold reduction in the number of false pos-
itive cases obtained with LDCT alone. Considering the
111 (3.3%) lung cancer cases detected during the ﬁrst 5
years of these two screening trials, 84 had a plasma
sample available to perform the MSC test. In this cohort
the MSC was able to predict the disease occurrence two
years before LDCT detection and the 5-year survival
was respectively 88.9% for low risk MSC, 79.5% for
intermediate risk MSC and 40.1% for high risk MSC
(p¼0.001).
Another possible use of liquid biopsy could be the
monitoring of the disease status after treatment or sur-
gical resection. The MSC test was thus employed to
analyze 100 longitudinally-collected plasma samples
obtained from 31 alive patients (28 disease-free and 3
relapsing) after surgical resection of primary lung tu-
mors. Considering the 25 disease-free patients positive
to the MSC test at the time of diagnosis, a reduction of
MSC risk proﬁle was observed in 19 (76%) post-surgery
plasma samples. Whereas in the 3 relapsing patients an
increase of the MSC risk level was observed at the time
of detection of second primary tumor or metastatic
progression.
So far the MSC test showed very promising results
in screening settings, being able to improve individ-
ual risk assessment and the performance of LDCT.
Further analysis will provide information about the
sensitivity of the MSC in clinically detected lung
cancer. The MSC risk levels are also being evaluated
according to other risk factors such as smoking
habits (measured as Pack Year), the inﬂammation
levels (measured as C-reactive protein) or the forced
expiratory volume (FEV-1). Finally, by targeted NGS
we are proﬁling the mutational load of screening
detected tumors in order to analyze association with
the MSC risk proﬁle.
